argenx SE (A1RG34) - Total Liabilities
Based on the latest financial reports, argenx SE (A1RG34) has total liabilities worth R$1.36 Billion BRL as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
argenx SE - Total Liabilities Trend (2021–2025)
This chart illustrates how argenx SE's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
argenx SE Competitors by Total Liabilities
The table below lists competitors of argenx SE ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MetLife Inc
NYSE:MET
|
USA | $716.25 Billion |
|
Itau Unibanco Banco Holding SA
NYSE:ITUB
|
USA | $2.86 Trillion |
|
Petroleo Brasileiro S.A.
MC:XPBRA
|
Spain | €147.99 Billion |
|
Discover Financial Services
NYSE:DFS
|
USA | $128.95 Billion |
|
Ferrovial SE
NASDAQ:FER
|
USA | $19.75 Billion |
|
NAURA Technology Group Co Ltd
SHE:002371
|
China | CN¥43.72 Billion |
|
BOC Hong Kong (Holdings) Limited
F:BOF
|
Germany | €4.13 Trillion |
|
Cardinal Health Inc
NYSE:CAH
|
USA | $60.78 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down argenx SE's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how argenx SE's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for argenx SE (2021–2025)
The table below shows the annual total liabilities of argenx SE from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | R$1.36 Billion | +93.06% |
| 2024-12-31 | R$704.24 Million | +58.27% |
| 2023-12-31 | R$444.95 Million | +38.80% |
| 2022-12-31 | R$320.56 Million | +1.43% |
| 2021-12-31 | R$316.05 Million | -- |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develo… Read more